VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Exelixis
EXEL
$10.2B
| $331K | 0.14% |
9,939
-5,059
| -34% | -$168K |
|
227
Ionis Pharmaceuticals
IONS
$9.76B
| $330K | 0.13% |
9,448
+1,439
| +18% | +$50.3K |
|
228
BioNTech
BNTX
$27B
| $330K | 0.13% |
2,897
-534
| -16% | -$60.8K |
|
229
Ligand Pharmaceuticals
LGND
$3.25B
| $330K | 0.13% |
3,080
-969
| -24% | -$104K |
|
|
BPMC
230
DELISTED
Blueprint Medicines
BPMC
| $329K | 0.13% |
3,777
+681
| +22% | +$59.4K |
|
|
SWTX
231
DELISTED
SpringWorks Therapeutics
SWTX
| $327K | 0.13% |
9,037
+622
| +7% | +$22.5K |
|
232
Iovance Biotherapeutics
IOVA
$901M
| $325K | 0.13% |
43,927
+4,858
| +12% | +$35.9K |
|
233
Amicus Therapeutics
FOLD
$2.46B
| $325K | 0.13% |
34,449
+3,510
| +11% | +$33.1K |
|
234
Aurinia Pharmaceuticals
AUPH
$1.63B
| $324K | 0.13% |
36,084
-25,477
| -41% | -$229K |
|
235
ADMA Biologics
ADMA
$4.03B
| $321K | 0.13% |
18,728
-11,824
| -39% | -$203K |
|
236
Legend Biotech
LEGN
$6.66B
| $321K | 0.13% |
9,852
+2,310
| +31% | +$75.2K |
|
237
Krystal Biotech
KRYS
$4.35B
| $316K | 0.13% |
2,016
+214
| +12% | +$33.5K |
|
238
Geron
GERN
$893M
| $316K | 0.13% |
89,198
+21,708
| +32% | +$76.8K |
|
239
Lexicon Pharmaceuticals
LXRX
$396M
| $314K | 0.13% |
425,269
+245,297
| +136% | +$181K |
|
240
Ultragenyx Pharmaceutical
RARE
$3.07B
| $314K | 0.13% |
7,457
-181
| -2% | -$7.62K |
|
241
Axsome Therapeutics
AXSM
$6.25B
| $313K | 0.13% |
3,705
-837
| -18% | -$70.8K |
|
242
Novavax
NVAX
$1.28B
| $312K | 0.13% |
38,765
+16,881
| +77% | +$136K |
|
243
Vertex Pharmaceuticals
VRTX
$102B
| $303K | 0.12% |
753
-1,723
| -70% | -$694K |
|
244
CRISPR Therapeutics
CRSP
$4.99B
| $303K | 0.12% |
7,702
+2,655
| +53% | +$105K |
|
245
Esperion Therapeutics
ESPR
$540M
| $302K | 0.12% |
137,120
+23,942
| +21% | +$52.7K |
|
246
Agios Pharmaceuticals
AGIO
$2.09B
| $301K | 0.12% |
9,160
+2,118
| +30% | +$69.6K |
|
247
ImmunityBio
IBRX
$2.27B
| $294K | 0.12% |
115,018
+58,911
| +105% | +$151K |
|
248
Morgan Stanley Direct Lending Fund
MSDL
$1.56B
| $286K | 0.12% |
13,820
+4,462
| +48% | +$92.2K |
|
249
New Fortress Energy
NFE
$672M
| $282K | 0.12% |
18,636
+11,093
| +147% | +$168K |
|
250
Y-mAbs Therapeutics
YMAB
$390M
| $280K | 0.11% |
35,789
+8,457
| +31% | +$66.2K |
|